News & Events

Many researchers in the Berlin-Brandenburg region are studying the microbiome, the community of microorganisms that reside on and in our bodies. Sofia Forslund from the Experimental and Clinical Research Center now hopes to improve networking among them by establishing a virtual microbiome institute.

Organoids help researchers understand biological processes in health and in disease. It is, however, difficult to influence the way in which they organize themselves into complex tissues. Now a group led by Nikolaus Rajewsky has found a new way to do so. They report their work in Nature Methods.

When the PRDM16 gene mutates, heart muscle cells undergo changes in their metabolism. This increases the risk of congenital heart failure in women more than men, as a ECRC research team led by Sabine Klaassen and Jirko Kühnisch reports in “Cardiovascular Research.”

An afternoon marked by innovation: Berlin's Mayor, Kai Wegner, visited the Max Delbrück Center on October 11, 2023, and subsequently inaugurated the BerlinBioCube innovation center on the Buch research campus. The BioCube, in close proximity, provides state-of-the-art laboratories and offices for life science startups and spin-offs, including those from the Max Delbrück Center.

Campus Berlin-Buch has a new incubator for life science start-ups: 8,000 square meters of state-of-the-art laboratory and office space have been built on the Science and Technology Campus. The BerlinBioCube was ceremonially opened on October 11, 2023 in the presence of the Governing Mayor.

A data gap that threatens timely diagnosis and treatment for half the population, the visibility of female researchers in Wikipedia, and myriads of microbes in and on our bodies – the Max Delbrück Center's program for the Berlin Science Week 2023 is focused on dimensions of diversity.

Scientists have created a new zebrafish xenograft platform to screen for novel treatments for an aggressive brain tumor called glioblastoma, according to a new study by the Gerhardt and De Smet labs published in “EMBO Molecular Medicine.”

The Berlin biotech Glycotope and the Max Delbrück Center have signed an agreement to explore the potential of combining Glycotope’s tumor-specific antibodies with CAR technology developed by the Max Delbrück Center. Their common goal: advancing immunotherapies against solid tumors.

People with hypertension are at the greatest risk of developing serious cardiovascular diseases. A team of researchers at the Experimental and Clinical Research Center are now investigating whether probiotics in food supplements can support drug therapies or even delay the need to start them.